MKI67 and neoplasm: The experimental schema for animal treatment is shown in Fig. 6B. LLS30 (30 mg/kg, administered intravenously daily for three weeks) significantly reduced tumor burden and decreased the number of Ki-67-positive cells (Fig. 6C-E).